Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Long-Term Debt Repayments (2020 - 2025)

Aytu Biopharma (AYTU) has disclosed Long-Term Debt Repayments for 6 consecutive years, with $465000.0 as the latest value for Q4 2025.

  • Quarterly Long-Term Debt Repayments changed 0.0% to $465000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.9 million through Dec 2025, down 88.36% year-over-year, with the annual reading at $1.9 million for FY2025, 88.19% down from the prior year.
  • Long-Term Debt Repayments for Q4 2025 was $465000.0 at Aytu Biopharma, roughly flat from $464000.0 in the prior quarter.
  • The five-year high for Long-Term Debt Repayments was $89.6 million in Q4 2021, with the low at -$73.6 million in Q1 2022.
  • Average Long-Term Debt Repayments over 5 years is $2.5 million, with a median of $268500.0 recorded in 2023.
  • The sharpest move saw Long-Term Debt Repayments surged 65306.57% in 2021, then tumbled 577.64% in 2022.
  • Over 5 years, Long-Term Debt Repayments stood at $89.6 million in 2021, then plummeted by 100.03% to -$26000.0 in 2022, then soared by 188.46% to $23000.0 in 2023, then soared by 1921.74% to $465000.0 in 2024, then changed by 0.0% to $465000.0 in 2025.
  • According to Business Quant data, Long-Term Debt Repayments over the past three periods came in at $465000.0, $464000.0, and $464000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.